No retraction, correction or concern found when last checked on Oct 19, 2026.

Plasmodium vivax in the Era of the Shrinking P. falciparum Map

Ric N. Price, Robert J. Commons, Katherine E. Battle and 2 more

Trends in Parasitology · 2020 · Review · CC BY

doi:10.1016/j.pt.2020.03.009

Abstract

Plasmodium vivax is an important cause of malaria, associated with a significant public health burden. Whilst enhanced malaria-control activities have successfully reduced the incidence of Plasmodium falciparum malaria in many areas, there has been a consistent increase in the proportion of malaria due to P. vivax in regions where both parasites coexist. This article reviews the epidemiology and biology of P. vivax, how the parasite differs from P. falciparum, and the key features that render it more difficult to control and eliminate. Since transmission of the parasite is driven largely by relapses from dormant liver stages, its timely elimination will require widespread access to safe and effective radical cure.

References 77

1.
Mapping the global endemicity and clinical burden of Plasmodium vivax, 2000–17: a spatial and temporal modelling study · 2019
No notice
2.
Global Epidemiology of Plasmodium vivax · 2016
No notice
3.
Mendis K, et al. The neglected burden of Plasmodium vivax malaria. Am J Trop Med Hyg. 2001;64:97-106.
Not in our library10.4269/ajtmh.2001.64.97
4.
World Malaria Report: 2013. 2013.
Not in our library
5.
Gunalan K, et al. Plasmodium vivax infections of Duffynegative erythrocytes: historically undetected or a recent adaptation? Trends Parasitol. 2018;34:420-429.
Not in our library10.1016/j.pt.2018.02.006
6.
Growing evidence of Plasmodium vivax across malaria-endemic Africa · 2019
Corrected
7.
Ding XC, et al. Defining the next generation of Plasmodium vivax diagnostic tests for control and elimination: Target product profiles. PLoS Negl Trop Dis. 2017;11:e0005516.
Not in our library10.1371/journal.pntd.0005516
8.
Michon P, et al. The risk of malarial infections and disease in Papua New Guinean children. Am J Trop Med Hyg. 2007;76:997-1008.
Not in our library
9.
Douglas NM, et al. Gametocyte dynamics and the role of drugs in reducing the transmission potential of Plasmodium vivax. J Infect Dis. 2013;208:801-812.
Not in our library10.1093/infdis/jit261
10.
White NJ, et al. Assessment of therapeutic responses to gametocytocidal drugs in Plasmodium falciparum malaria. Malar J. 2014;13:483.
Not in our library10.1186/1475-2875-13-483
11.
Collins WE, et al. Experimental infection of Anopheles farauti with different species of Plasmodium. J Parasitol. 2002;88:295-298.
Not in our library10.1645/0022-3395(2002)088[0295:eioafw]2.0.co;2
12.
Bousema T, Drakeley C. Epidemiology and infectivity of Plasmodium falciparum and Plasmodium vivax gametocytes in relation to malaria control and elimination. Clin Microbiol Rev. 2011;24:377-410.
Not in our library10.1128/cmr.00051-10
13.
Sattabongkot J, et al. Plasmodium vivax transmission: chances for control? Trends Parasitol. 2004;20:192-198.
Not in our library10.1016/j.pt.2004.02.001
14.
Bockarie MJ, Dagoro H. Are insecticide-treated bednets more protective against Plasmodium falciparum than Plasmodium vivax-infected mosquitoes? Malar J. 2006;5:15.
Not in our library10.1186/1475-2875-5-15
15.
Determinants of relapse periodicity in Plasmodium vivax malaria · 2011
No notice
16.
Geographical variation in Plasmodium vivax relapse · 2014
No notice
17.
Shanks GD, White NJ. The activation of vivax malaria hypnozoites by infectious diseases. Lancet Infect Dis. 2013;13:900-906.
Not in our library10.1016/s1473-3099(13)70095-1
18.
Commons RJ, et al. Risk of Plasmodium vivax parasitaemia after Plasmodium falciparum infection: a systematic review and meta-analysis. Lancet Infect Dis. 2019;19:91-101.
Not in our library10.1016/s1473-3099(18)30596-6
19.
Hossain MS, et al. The risk of Plasmodium vivax parasitaemia after Plasmodium falciparum infection: an individual patient data meta-analysis. 2019.
Not in our library
20.
The probability of a sequential Plasmodium vivax infection following asymptomatic Plasmodium falciparum and P. vivax infections in Myanmar, Vietnam, Cambodia, and Laos · 2019
Not checked
21.
Douglas NM, et al. Plasmodium vivax recurrence following falciparum and mixed species malaria: risk factors and effect of antimalarial kinetics. Clin Infect Dis. 2011;52:612-620.
Not in our library10.1093/cid/ciq249
22.
Baird JK. Evidence and implications of mortality associated with acute Plasmodium vivax malaria. Clin Microbiol Rev. 2013;26:36-57.
Not in our library10.1128/cmr.00074-12
23.
Anstey NM, et al. Plasmodium vivax: clinical spectrum, risk factors and pathogenesis. Adv Parasitol. 2012;80:151-201.
Not in our library10.1016/b978-0-12-397900-1.00003-7
24.
Baird JK. 8-Aminoquinoline therapy for latent malaria. Clin Microbiol Rev. 2019;32:e00011-e00019.
Not in our library10.1128/cmr.00011-19
25.
Patriani D, et al. Early and late mortality after malaria in young children in Papua, Indonesia. BMC Infect Dis. 2019;19:922.
Not in our library10.1186/s12879-019-4497-y
26.
Douglas NM, et al. Mortality attributable to Plasmodium vivax malaria: a clinical audit from Papua, Indonesia. BMC Med. 2014;12:217.
Not in our library10.1186/s12916-014-0217-z
27.
Major Burden of Severe Anemia from Non-Falciparum Malaria Species in Southern Papua: A Hospital-Based Surveillance Study · 2013
No notice
28.
Adverse effects of falciparum and vivax malaria and the safety of antimalarial treatment in early pregnancy: a population-based study · 2012
No notice
29.
Multidrug-Resistant Plasmodium vivax Associated with Severe and Fatal Malaria: A Prospective Study in Papua, Indonesia · 2008
No notice
30.
Plasmodium vivax and Mixed Infections Are Associated with Severe Malaria in Children: A Prospective Cohort Study from Papua New Guinea · 2008
No notice
31.
Dini S, et al. The risk of morbidity and mortality following recurrent malaria in Papua, Indonesia: a retrospective cohort study. BMC Med. 2020;18:28.
Not in our library10.1186/s12916-020-1497-0
32.
World Malaria Report 2019. 2019.
Not in our library
33.
Malaria in Brazil: an overview · 2010
No notice
34.
Rodriguez JC, et al. Epidemiology and control of malaria in Colombia. Mem Inst Oswaldo Cruz. 2011;106:114-122.
Not in our library10.1590/s0074-02762011000900015
35.
Kenangalem E, et al. Malaria morbidity and mortality following introduction of a universal policy of artemisinin-based treatment for malaria in Papua, Indonesia: A longitudinal surveillance study. PLoS Med. 2019;16:e1002815.
Not in our library10.1371/journal.pmed.1002815
36.
Ome-Kaius M, et al. Differential impact of malaria control interventions on P. falciparum and P. vivax infections in young Papua New Guinean children. BMC Med. 2019;17:220.
Not in our library10.1186/s12916-019-1456-9
37.
Chu CS, et al. Declining burden of Plasmodium vivax in a population in Northwestern Thailand from 1995 to 2016 before comprehensive primaquine prescription for radical cure. Am J Trop Med Hyg. 2019;102:147-150.
Not in our library10.4269/ajtmh.19-0496
38.
Strategies for Understanding and Reducing the Plasmodium vivax and Plasmodium ovale Hypnozoite Reservoir in Papua New Guinean Children: A Randomised Placebo-Controlled Trial and Mathematical Model · 2015
No notice
39.
Adekunle AI, et al. Modeling the dynamics of Plasmodium vivax infection and hypnozoite reactivation in vivo. PLoS Negl Trop Dis. 2015;9:e0003595.
Not in our library10.1371/journal.pntd.0003595
40.
Douglas NM, et al. Chemotherapeutic strategies for reducing transmission of Plasmodium vivax malaria. Adv Parasitol. 2012;80:271-300.
Not in our library10.1016/b978-0-12-397900-1.00005-0

All 77 references

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.